medigraphic.com
Instituto Nacional de Salud Pública

2012, Number 3

<< Back Next >>

salud publica mex 2012; 54 (3)

Smoking cessation interventions in Mexico: Analysis of the willingness to pay for an effective method to quit

Serván-Mori EE, Heredia-Pi IB, Reynales-Shigematsu LM, Bautista-Arredondo S

Language: Spanish
References: 33
Page: 213-224
PDF size: 227.57 Kb.


ABSTRACT

Objective. To identify environmental, demographic and socioeconomic factors associated with the desire to quit, estimate the willingness to pay (WTP) for smoking cessation treatments (SCT) and to identify associated factors with this valuation. Materials and methods. Using the Global Adult Tobacco Survey, Mexico 2009, we characterized 1 626 smokers. Logistic and multiple lineal regression models allowed to identify associated factors with the desire to quit and the WTP for SCT. Results. 82.2 % of the current smokers who did not want to quit were men. Between those who wanted to quit, 49.8 % had been consuming tobacco every day, for more than 16 years, 57 % had made cessation attempts in the past, and around 10% knew about the existence of centers to help quit smoking. Average WTP was 2 708 Mexican pesos (MXP), with differences by educational and socioeconomic levels. Conclusions. This evidence supports policymakers in the design of smoking cessation interventions improving national health system interventions for quit smoking.


REFERENCES

  1. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva: World Health Organization, 2003.

  2. WHO Report on the Global Tobacco Epidemic, 2008 - The MPOWER package. [Consultado 12 de agosto de 2009] Disponible en: http://www.who.int/tobacco/mpower/en/.

  3. Regalado-Pineda J, Lara-Rivas G, Osio-Echánove J, Ramírez-Venegas A. Tratamiento actual del tabaquismo. Salud Publica Mex 2007;49(supl 2):S270-S279.

  4. Sansores RH, Ramírez-Venegas A, Espinosa- Martínez M, Sandoval RA. Tratamientos para dejar de fumar disponibles en México. Salud Publica Mex 2002;44( S1):116-124.

  5. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-691.

  6. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation. Arch Intern Med 2006;166:1571-1577.

  7. West R. ABC of smoking cessation. Assessment of dependence and motivation to stop smoking. BMJ 2004;328:338-339.

  8. Encuesta Nacional de Adicciones 2008. Instituto Nacional de Salud Pública, Cuernavaca, México. [Consultado: 2 de noviembre de 2009]. Disponible en http://www.insp.mx/Portal/Inf/ENA08_nacional.pdf.

  9. Organización Panamericana de la Salud, Instituto Nacional de Salud Pública (MX). Encuesta Global de Tabaquismo en Adultos. México 2009. Cuernavaca (México): Instituto Nacional de Salud Pública, 2010. Coeditado con la Organización Panamericana de la Salud, 2010. [Consultado: 8 de octubre de 2010]. Disponible en: http://www.insp.mx/images/stories/INSP/Docs/GATS.pdf.

  10. US Department of Health and Human Services. The Health Benefits of Smoking Cessation. A report of the Surgeon General, 1990. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. [Consultado: 20 de mayo de 2008]. Disponible en: http://profiles.nlm.nih.gov/NN/B/B/C/T/_/nnbbct.pdf.

  11. Centers for Disease Control and Prevention. Smoking cessation during previous year among adults-United States, 1990 and 1991. Morb Mortal Wkly Rep 1993;42:504-507.

  12. González-Enríquez J, Salvador-Llivina T, López-Nicolás A, Antón de las Heras E, Musin A, Fernández E, et al. Morbilidad, mortalidad y costes sanitarios evitables mediante una estrategia de tratamiento del tabaquismo en España. Gac Sanit 2002;16(4):308-317.

  13. Antoñanzas F, Portillo F. Evaluación económica del empleo de terapias farmacológicas para la cesación en el hábito tabáquico. Gac Sanit 2003;17(5):393-403

  14. Arrow K, Solow R, Portney PR, Leamer EE, Radner R, Schuman H. Report of the NOAA panel of contingent valuation. Federal Register 1993;58:4601-4614.

  15. Smith RD Sach TH. Contingent Valuation: (Still) on the Road to nowhere? Health Econ 2009;18:863-866.

  16. Frew E, Wolstenholme JL, Whynes DK. Willingness-to-pay for colorectal cancer screening. Eur J Cancer 2001;37:1746-1751.

  17. Frew EJ, Whynes DK, Wolstenholme JL .Eliciting Willingness to Pay: Comparing Closed-Ended with Open-Ended and Payment Scale Formats. Med Decis Making 2003;23:150-159.

  18. Whynes DK, Frew EJ, Wolstenholme JL. Willingness-to-Pay and Demand Curves: A Comparison of Results Obtained Using Different Elicitation Formats. Int J Health Care Finance Econ 2005;(5):369-386.

  19. Busch SH, Falba TA, Duchovny N, Jafre-Bonet M, O’Malley SS, Sindelar JL. Value to smokers of improved cessation products: evidence from a willingness-to-pay survey. Nicotine Tob Res 2004:6(4):631-639.

  20. Weimer DL, Vining AR, Thomas RK. Cost-Benefit Analysis involving addictive goods: contingent valuation to estimate willingness to pay for smoking cessation. Health Econ 2009;18:181-202.

  21. Avila-Burgos L, Gutiérrez-Zúñiga C, Hernández-Peña P, Santos-Burgoa C, Silvia-Aycaguer L. El costo social de la bronquitis crónica en la Ciudad de México: una experiencia piloto. Salud Publica Mex 1996;128-138.

  22. Vargas-Bustamante A, Ojeda G, Castañeda X. Willingness to pay for cross border health insurance between the United States and Mexicoel futuro Estados Unidos y México los programas de inmigración. Health Affairs 2008;27(1)1(2008):169-178;10.1377/hlthaff.27.1.169]:169-178.

  23. Vásquez WF, Mozumder P, Hernández-Arce J, Berrens RP. Willingness to pay for safe drinking water: Evidence from Parral, Mexico. J Environ Manage 2009;90(11):3391-3400.

  24. Kolenikov S, Angeles G. The use of discrete data in PCA: theory, simulations, and applications to socioeconomic indices. Chapel Hill: Carolina Population Center, University of North Carolina, 2004.

  25. McKenzie, D. Measuring inequality with assets indicators. J Pop Econ 2005;18:229-260.

  26. Filmer D, Pritchett LH. Estimating wealth effect without expenditure data – or tears: an application to educational enrollments in states of India. Demography 2001;38:115-132.

  27. Hotelling H. Analysis of a complex of statistical variables into principal components. J Educ Psychol 1933;24:417-441,498-520.

  28. Anderson TW. An Introduction to Multivariate Statistical Analysis, 3rd edn. New York: John Wiley and Sons, 2003.

  29. Mardia KV, Kent JT, Bibby J. M. Multivariate Analysis. London: Academic Press, 1980.

  30. World Health Organization. Tools for Advancing Tobacco Control in the XXIst century: Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence. Tools for public health. WHO, 2003. [Consultado: 28 de septiembre de 2011]. Disponible en: http://www.who.int/tobacco/resources/publications/tobacco_dependence/en/

  31. Instituto Mexicano del Seguro Social. Cuadro Básico Institucional de Medicamentos. [Consultado: 9 de marzo de 2009]. Disponible en: http://www.imss.gob.mx/transparencia/CuadrosBasicos/medicamentos.htm.

  32. Cutler DM, Gruber J. Does Public Insurance Crowd Out Private Insurance? Q J Econ 1996;111:391-430.

  33. Dubay L, Kenney G. The Effects of Medicaid Expansions on Insurance Coverage of Children. Future Child 1996;6(1):152-161.




2020     |     www.medigraphic.com